Roma Green Finance Ltd ROMA
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.07
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $1.6M | $1.3M | — | — |
| Cost of revenue | $1.0M | $985.7K | $869.4K | — | — |
| Gross profit | $208.5K | $578.7K | $400.3K | — | — |
| SG&A | $2.4M | $2.0M | $905.5K | — | — |
| Total operating expenses | $4.0M | $4.2M | $1.2M | — | — |
| Operating income | -$3.8M | -$3.7M | -$780.9K | -$173.7K | — |
| Pre-tax income | -$3.5M | -$3.6M | -$748.7K | — | — |
| Income tax | — | $150 | — | — | — |
| Net income | -$3.5M | -$3.6M | -$748.7K | — | — |
| EPS, basic | -0.07 | -0.26 | -0.09 | — | — |
| EPS, diluted | -0.07 | -0.26 | -0.09 | — | — |
| Shares, diluted (wtd. avg.) | $51.6M | $13.6M | $8.1M | $6.6M | $6.6M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $884.4K | $2.7M | $5.5M | $68.0K | — |
| Receivables | $269.3K | $239.0K | $193.6K | — | — |
| Total current assets | $8.1M | $6.4M | $7.6M | — | — |
| Property, plant and equipment | $3.1K | $3.8K | $6.0K | — | — |
| Goodwill | $1.7M | — | — | — | — |
| Other intangibles | $126.0K | — | — | — | — |
| Total assets | $10.0M | $6.5M | $8.1M | — | — |
| Accounts payable | $26.4K | $26.4K | — | — | — |
| Total current liabilities | $364.6K | $259.7K | $701.1K | — | — |
| Total liabilities | $364.6K | $259.7K | $701.1K | — | — |
| Retained earnings | -$8.0M | -$4.5M | -$982.5K | — | — |
| Total equity | $9.6M | $6.2M | $7.4M | — | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$2.5M | -$1.6M | -$3.2M | — | — |
| Depreciation and amortisation | $2.2K | $2.1K | $3.9K | — | — |
| Stock-based compensation | — | $1.2M | — | — | — |
| Capital expenditure | $1.5K | — | $785 | — | — |
| Investing cash flow | -$6.1M | -$2.4M | -$785 | — | — |
| Financing cash flow | $6.9M | $1.2M | $8.7M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-035563.
Others in SIC 8742
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| BAH | Booz Allen Hamilton Holding Corp | $8.76B | 10.6x | -6.4% |
| G | Genpact LTD | $6.27B | 11.9x | 6.6% |
| FCN | FTI CONSULTING, INC | $4.19B | 18.4x | 2.4% |
| EXPO | EXPONENT INC | $3.25B | 33.0x | 4.2% |
| HURN | Huron Consulting Group Inc. | $2.52B | 26.6x | 11.9% |
| ASTH | Astrana Health, Inc. | $2.14B | 83.6x | 56.4% |
| ICFI | ICF International, Inc. | $1.58B | 17.8x | -7.3% |
| BWMN | Bowman Consulting Group Ltd. | $735.5M | 58.1x | 14.9% |